ArticleBMC cancer2022

HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.

François Cherifi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.